Join us at ASCRS 2025 in Los Angeles!
We are bringing innovation, expertise, and hands-on learning to ASCRS 2025! From April 25–27, visit us for expert-led discussions, live demonstrations, and peer-to-peer connections—all designed to enhance your knowledge and skills.
__________
Don’t Miss These Eight Insightful Events
__________
Visit our booth on Saturday morning for an engaging discussion on interventional glaucoma, MIGS, and canal surgery. Gain expert insights into proactive glaucoma treatment strategies—including the use of OMNI in patients with POAG—and explore the expanding role of interventional approaches in today’s evolving treatment landscape. Enjoy lunch while enhancing your knowledge and surgical skills—don’t miss it!
__________
Exciting news! We are expanding our OMNI portfolio with the launch of the OMNI Edge Surgical System at ASCRS, and we invite you to join the celebration. Visit our booth for the official unveiling and a toast to our shared commitment to advancing eyecare for the benefit of patients. Enjoy appetizers, network with leading physicians, industry experts, and media, and be among the first to explore this latest glaucoma innovation. We look forward to celebrating with you!
__________
Join us at our booth for the exciting peer-to-peer TearCare Clearance Experience Sessions. Your peers will share firsthand insights, best practices, and pro tips on seamlessly integrating TearCare into your practice. Learn directly from them how to optimize patient outcomes, navigate the evolving interventional treatment landscape, and unlock new opportunities in MGD.
__________
We are pleased to have presentations at ASCRS highlighting robust clinical data supporting the use of OMNI and TearCare. Don’t miss these opportunities to learn from the experts.
__________
Join us for an interactive "how-to" session designed to provide a clear, practical framework for implementing pseudophakic MIGS into your practice. Walk away with the confidence to optimize care for your pseudophakic glaucoma patients and discover the value of partnering with Sight Sciences to drive meaningful change.
__________
__________
Gagan Sawhney, MD will share insights about the benefits of interventional glaucoma and performing implant-free, minimally invasive procedures with OMNI and SION technologies, now available to all EyeProGPO members. Don't miss this opportunity to learn how these innovative technologies can enhance your practice!
__________
OMNI will be featured in three MIGS Skills Transfer Courses. These hands-on courses are part of the official ASCRS CME program and offers participants a unique opportunity to learn and practice using various devices for Minimally Invasive Glaucoma Surgery (MIGS), including the OMNI.
Discover the Power of OMNI, SION, and TearCare
At Sight Sciences, we are committed to delivering transformative solutions for interventional glaucoma, goniotomy innovation, or ocular surface disease management. Join us at Booth 2439 to explore our latest advancements.
OMNI® Surgical System
Enables an implant-free, ab interno MIGS procedure that targets three areas of outflow resistance (Schlemm’s canal, collector channels, and trabecular meshwork).
SION® Surgical Instrument
A new chapter in goniotomy is here. With its signature bladeless design, SION was designed to offer an intuitive surgical experience and facilitate a smooth, gentle goniotomy.
TearCare® System
Clinically proven superiority in treating MGD associated OSD.1 TearCare delivers the long-lasting relief you and your patients need. Visit our booth for a live TearCare clearance experience session.
Sight Sciences Mission
We have embarked on a journey to reimagine the landscape of eyecare. Our mission is clear: to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing. We envision a future where innovations are not only groundbreaking but are also employed at the earliest stages of disease progression, ensuring safe and unprecedented progress in the field of vision health.
Contact Us
Please fill out this form to schedule a demo, request a meeting, or receive more information. See you at ASCRS!
Important Information
All the physicians are paid consultants of Sight Sciences. These events are neither sponsored nor endorsed by ASCRS.
The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Visit omnisurgical.com/ifu for the indications for use, contraindications, warnings, and potential adverse events. The SION® Surgical Instrument is a sterile, single use, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. Visit sionsurgical.com/ifu for the indications for use, contraindications, warnings, and potential adverse events. The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. The TearCare® System may not be right for everyone. Please see Instructions for Use or visit TearCare.com for Contraindications, Warnings, Precautions and Adverse Events.
03/2025 SS-3390-US.v1
__________
References
*SAHARA eligibility required a minimum of 15 expressible glands in each lower eyelid
- Ayres, B. D., Bloomenstein, M. R., Loh, J., Chester, T., Saenz, B., Echegoyen, J., Kannarr, S. R., Perez, V. L., Rodriguez, T. C., & Dickerson, J. E., Jr (2023). A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA). Clinical ophthalmology (Auckland, N.Z.), 17, 3925–3940.
- Ayres, B. D., Bloomenstein, M. R., Loh, J., Chester, T., Saenz, B., Echegoyen, J., Kannarr, S. R., Rodriguez, T. C., & Dickerson, J. E., Jr (2024). Improved Signs and Symptoms of Dry Eye Disease for Restasis® Patients Following a Single Tearcare® Treatment: Phase 2 of the SAHARA Study. Clinical ophthalmology (Auckland, N.Z.), 18, 1525–1534.
__________
Have Questions?
For questions or additional information, email us at blog@sightsciences.com